Current Clinical Trials
All Clinical Trials
Melanoma
Name of this trial: OptimUM-10
What type of cancer is this for? Uveal Melanoma
Who is this trial for? Subjects with Primary Non-metastatic Uveal Melanoma
What biomarkers are involved? Monosomy 3
What is the National Clinical Trial #? NCT07015190; https://clinicaltrials.gov/study/NCT07015190
Brief summary of this trial: A Randomized, Phase 3, Open-label Study of Neoadjuvant Darovasertib in Subjects with Primary Non-metastatic Uveal Melanoma
Need to know: Must be at high risk of metastasis defined by at least one of the following: Monosomy 3, Class 2 GEP, Stage 3 by AJCC. Must not have had previous treatment for uveal melanoma or have evidence of metastatic uveal melanoma.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email [email protected]
Name of this trial: IDE 196-001
What type of cancer is this for? Metastatic Uveal Melanoma
Who is this trial for? Patients with confirmed metastatic disease which progresses on or after most recent treatment, or for patients with no treatment in the metastatic setting.
What biomarkers are involved? GNAQ/11
What is the National Clinical Trial #? NCT03947385
Brief summary of this trial: Patients eligible for this trial will receive investigational oral drug IDE196 plus Crizotinib (oral drug), both drugs will be taken twice daily.
Need to know: All potentially eligible patients will have tumor and blood samples sent to central laboratory for confirmation of GNAQ/11. First couple weeks on trial will include long days in clinic and eye exams will be required every 4 weeks.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email [email protected]
Multiple Myeloma
Name of this trial: Majestic-7
What type of cancer is this for? Multiple Myeloma
Who is this trial for? This trial is for patients with newly diagnosed multiple myeloma who are either ineligible or not intended for stem cell transplant as initial therapy.
What biomarkers are involved? n/a
What is the National Clinical Trial #? NCT05552222
Brief summary of this trial: This is a phase 3 randomized trial, comparing Teclistamab in combination with Daratumumab injection and lenalidomide (oral) VS. Talquetamab in combination with Daratumumab injection and lenalidomide (oral), No placebo in this trial, all patients will receive treatment.
Need to know: Teclistamab and Talquetamab are both injection medications, not IV. Both drugs recently approved to be given in outpatient setting and no longer requiring hospitalization for monitoring. Home monitoring of vital signs and required family member presence/driving after first 3 doses to ensure patient safety. First 3-4 weeks of treatment has a busy schedule, however after first cycle visits are more spaced out.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email [email protected]
Name of this trial: EXCALIBER-Maintenance
What type of cancer is this for? Newly diagnosed Multiple Myeloma (NDMM)
Who is this trial for? 1) Patients who have received 3 to 6 cycles of an induction therapy. Post-stem cell transplant consolidation is permitted. 2) Patients within 12 months from initiation of induction who achieved at least a partial response after Autologous Stem Cell Transplantation, with or without consolidation.
What biomarkers are involved? None
What is the National Clinical Trial #? NCT05827016
Brief summary of this trial: The study is comparing Iberdomide maintenance vs. Lenalidomide maintenance therapy after Autologous Stem Cell Transplantation (ASCT) in patients with newly diagnosed multiple myeloma.
Need to know: Patients will be randomized 50:50 to either Iberdomide or Lenalidomide. Both medications are oral drugs, Iberdomide is taken 21 days out of a 28-day cycle, and Lenalidomide is taken 28 days out of a 28-day cycle. Treatment continues until progression of disease or until medications are not tolerated by patient.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email [email protected]
Myelofibrosis
Name of Trial: Karyopharm XPORT-MF-034
What type of Cancer is this for? Myelofibrosis (Blood cancer)
Phase: 3
Who is this trial for? Patients with myelofibrosis or post-essential thrombocythemia (ET) or postpolycythemia-vera (PV) myelofibrosis.
What biomarkers involved? None
What is the National Clinical Trial #? NCT04562389
Brief Summary: Purpose of this study is to evaluate the drug Selinexor in combination with Ruxolitinib vs. Placebo plus Ruxolitinib. This is a double-blinded randomized clinical trial with 2:1 ratio.
Need to know: This trial is for patients who have not yet had any treatment for their blood cancer.
Where is this trial available? This trial is available at The Cancer and Hematology at Lemmon-Holton Cancer Pavilion, and at The Cancer and Hematology Centers in Muskegon. This trial is also available at other sites nationwide.
For more information, please call 616-975-3065 or email [email protected]
Pancreas
Name of this trial: MountainTap-30
What type of cancer is this for? Pancreatic Cancer
Who is this trial for? Patients with treatment naïve metastatic pancreatic cancer
What biomarkers are involved? MTAP deletion
What is the National Clinical Trial #? NCT07076121 https://clinicaltrials.gov/study/NCT07076121?term=NCT07076121&rank=1
Brief summary of this trial: A Randomized, Phase 2/3 Study Comparing BMS-986504 in Combination with Nab-paclitaxel and Gemcitabine versus Placebo in Combination with Nab-paclitaxel and Gemcitabine in Participants with Untreated Metastatic Pancreatic Ductal Adenocarcinoma Harboring Homozygous MTAP Deletion
Need to know: Patients must not have received any treatment in the metastatic setting. Must have MTAP deletion which will be verified through central testing.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065
Prostate
Name of this trial: Ideate-Prostate-01
What type of cancer is this for? Prostate Cancer
Who is this trial for? Patients with metastatic castration-resistant prostate cancer
What biomarkers are involved? n/a
What is the National Clinical Trial #? NCT06925737
Brief summary of this trial: A Phase 3, Open-label Study of Ifinatamab Deruxtecan Versus Docetaxel in Participants with Metastatic Castration-Resistant Prostate Cancer (mCRPC).
Need to know: Must have had progression of disease while on androgen deprivation therapy (ADT)(or post bilateral orchiectomy) within 6 months prior to entering study. Has received prior treatment with 1 or 2 androgen receptor pathway inhibitor (ARPI) and progressed during or after at least 8 weeks of treatment.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email [email protected]
Name of this trial: MK-5684-004
What type of cancer is this for? PROSTATE cancer
Phase of this trial? Phase III
Who is this trial for? Men with prostate cancer that has spread while taking a next generation hormonal agent.
What biomarkers are involved? None
What is the National Clinical Trial# NCT06136650
Brief summary of trial: This trial is comparing the study drug (MK-5684) to two other drugs, looking to prove that the study drug helps men live longer. It is randomized 1:1.
Need to know: Your prostate cancer must be castration resistant (cancer that continues to grow even when the testosterone levels are at or below the castrate level) and your disease has to have progressed when you were on or after you received a Next Generation Hormonal Agent such as enzalutamide, abiraterone acetate, apalutamide, and darolutamide.
Where is this trial available?: The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email [email protected]
Registry Trial
NAME: EXACT- Registry trial
What kind of cancer is this for? All cancer types
Phase: N/A
Who is this trial for? Men and women who either have a diagnosis of cancer, a clinical suspicion of cancer, a diagnosis of recurrent cancer or a clinical suspicion of recurrent cancer.
What biomarkers are involved? Multiple
What is National Clinical Trial #?
Brief summary of trial: This study is looking at tissue and blood samples from cancer patients, to study the biomarkers they find in the blood or tissue to help and come up with future therapies.
Need to know: There are no medications in this trial, you would need to give a blood or tissue sample for the sponsor to evaluate.
Where is this trial available? The Cancer & Hematology Centers
For more information, please call 616-975-3065 or email [email protected]
NAME: Oracle- Registry trial
What kind of cancer is this for? All types
Phase: N/A
Who is this trial for? The primary study population will include participants with invasive bladder, ureteral, or renal pelvis carcinoma, non-small cell lung cancer, and breast cancer. Exploratory cohorts include participants with cutaneous melanoma, esophageal carcinoma, gastroesophageal junction carcinoma, gastric adenocarcinoma, pancreatic adenocarcinoma, squamous cell carcinoma of the head and neck, epithelial ovarian/Fallopian tube carcinoma, endometrial cancer, renal cell carcinoma (RCC), and rectal adenocarcinoma.
What biomarkers are involved? None
What is National Clinical Trial #? NCT05059444
Brief summary of trial: This study wants to test an assay that they have developed, which could help detect recurrence in people with certain tumors.
Need to know: There are no medications on this trial, just blood draws and tissue samples are needed.
Where is this trial available? The Cancer & Hematology Centers
For more information, please call 616-975-3065 or email [email protected]
Biliary Tract Cancer Clinical Trials
Biliary Tract
Name of this trial: Destiny-BTC
What type of cancer is this for? Biliary Tract Cancer
Who is this trial for? First line for locally advanced or metastatic HER2 expressing biliary tract cancer
What biomarkers are involved? HER2 positive (expressing)
What is the National Clinical Trial #? NCT06467357
Brief summary of this trial: Phase 3 trial of trastuzumab deruxtecan and rilvegostomig Vs standard of care treatment. This is an open-label design with randomization into 1 of 2 arms.
Need to know: May have had prior treatment in the perioperative and/or adjuvant setting, but no treatment in the locally advanced or metastatic space.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email [email protected]
NAME: PanTumor3- Biliary Tree
What type of cancer is this for: Liver, gallbladder, bile ducts
Phase: II
Who is this trial for: Men and women who have cancer in their biliary tract: liver and/or gallbladder and/or bile ducts that has spread to other parts of the body and cannot be taken out.
What biomarkers are involved? Your cancer cells must be positive for Trop2
What is National Clinical Trial #? NCT05489211
Brief summary of trial: This trial is looking to see how well the study drug (Dato-DXd) works on biliary tract cancers that have spread, as well as how safe the drug is.
Need to know: You need to have tried either Gemzar & Carboplatin OR Gemzar & Cisplatin in the past.
Where is this trial available? The Cancer & Hematology Centers
For more information, please call 616-975-3065 or email [email protected]
Bladder Cancer Clinical Trials
Breast Cancer Clinical Trials
Breast
Name of this trial: Katsis-1
What type of cancer is this for? Breast Cancer
Who is this trial for? Subjects With Locally Advanced or Metastatic Breast Cancer
What biomarkers are involved? ER+, HER2-
What is the National Clinical Trial #? NCT07062965 https://clinicaltrials.gov/study/NCT07062965?term=NCT07062965&rank=1
Brief summary of this trial: Phase 3, open-label, randomized study of PF-07248144 + Fulvestrant, compared to investigators choice of therapy in patients who are ER+, HER2-, advanced/metastatic breast cancer who have progressed after prior CDK4/6 inhibitor-based therapy.
Need to know: Locally advanced or metastatic disease that is not amenable by surgery. Must have received prior CDK4/6i, plus endocrine therapy in advanced/metastatic setting, or adjuvant CDK4/6i OR endocrine therapy with documented progression within 12 months of last dose of CDK4/6i.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email [email protected]
Name of this trial: INAVO123
What type of cancer is this for? Breast Cancer
Who is this trial for? Patients with locally advanced or metastatic breast cancer.
What biomarkers are involved? PIK3CA-positive, ER+, HER2-
What is the National Clinical Trial #? NCT06790693
Brief summary of this trial: This is a blinded trial that consists of 2 potential arms to be randomized. Arm 1 is with Inavolisib (study drug) + Letrozole + palbociclib; VS Arm 2 Placebo + Letrozole + palbociclib.
Need to know: ER and/or PR positive, HER2 negative breast cancer patients after at least 2 years of standard endocrine therapy (i.e., tamoxifen, anastrozole, letrozole, exemestane, and/or oral selective estrogen receptor degrader) without disease progression during that treatment and disease-free interval of at least 1 year since completion of that treatment.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email [email protected]
Name of Trial? Capitello-292
Phase of this trial? Phase 3
Who is this trial for? Men and Women with hormone positive, HER2 negative breast cancer that is locally advanced and inoperable.
What biomarkers are involved? None
Clinical Trial # NCT04862663
Brief Summary of Trial: This is a randomized 1:1 trial that is looking at new drug Capivasertib in combination with anti-hormone drug and a CDK4/6 inhibitor (oral drug), vs. anti-hormone drug plus CDK4/6 inhibitor. The study is looking for which works best.
Need to Know: Must have relapsed on or within 12 months of completing first line endocrine therapy (such as Tamoxifen, or another AI), maximum of 1 line of chemotherapy in advanced disease setting.
Where is this trial available? Cancer and Hematology Centers and other sites nationwide, please click on link for other locations,
For more information, please call 616-975-3065 or email [email protected]
Name of this trial: ELAINE 3
What type of cancer is this for? BREAST
Phase of this trial: Phase III
Who is this trial for? Men and Women with Breast Cancer that has spread to other parts of the body.
What biomarkers are involved? You must have estrogen receptor positive, HER2 negative Breast Cancer with an ESR1 Mutation
What is National Clinical Trial #? NCT05696626
Brief summary of trial: This trial compares how effective and safe the combination of Lasofoxifene and Abemaciclib is, compared to the combination of Fulvestrant and Abemaciclib. Lasofoxifene and Abemaciclib are both pills, and Fulvestrant is an injection.
Need to know: You must have tried Ribociclib or palbociclib-based treatment before.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email [email protected]
Name of this trial: GILEAD ASCENT-05
What type of cancer is this for? BREAST Cancer Triple Negative
Phase of this trial: Phase III
Who is this trial for? Men and Women with Breast Cancer early stage not cured with chemotherapy and surgery.
What biomarkers are involved? You must have estrogen receptor negative, progesterone receptor negative, and HER2 negative Breast Cancer
What is National Clinical Trial #? NCT05633654
Brief summary of trial: This trial compares how effective and safe the combination of Sacituzumab Govitecan and Pembrolizumab is, compared to treatment of physician’s choice in patients with triple negative breast cancer who have residual invasive disease after surgery and neoadjuvant therapy.
Need to know: Must have had neoadjuvant treatment and surgery for breast surgery with residual disease.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email [email protected]
Colorectal Cancer Clinical Trials
Colorectal
Name of this trial: Origami-2
What type of cancer is this for? Colorectal Cancer
Who is this trial for? Patients with Unresectable or Metastatic Left-sided Colorectal Cancer
What biomarkers are involved? KRAS/NRAS and BRAF Wild-type
What is the National Clinical Trial #? NCT06662786
Brief summary of this trial: Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
Need to know: Be diagnosed to have KRAS, NRAS, and BRAF WT tumor as determined by local testing. The last course of adjuvant or neoadjuvant chemotherapy must have concluded >12 months prior to CTC recurrence/metastases.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email [email protected]
Name of this trial: Oragami-3
What type of cancer is this for? Recurrent Metastatic Colorectal Cancer
Who is this trial for? Patients Who Have Received or Intolerant to Prior Chemotherapy
What biomarkers are involved? Wild-type KRAS/NRAS, BRAF
What is the National Clinical Trial #? NCT06750094
Brief summary of this trial: Randomized, open-label trial of Amivantamab (investigational drug) + chemotherapy, vs. Cetuximab/Bevacizumab (Standard of care, comparator) + chemotherapy, for patients who have recurrent, unresectable or metastatic colorectal cancer.
Need to know: Patients must have received 1 previous line of treatment for metastatic disease, and randomization is 50/50 between the 2 arms of therapy. This is open label, there is no placebo given and patients will know which medications they are receiving. Investigational medication Amivantamab is an injection that goes into abdomen, and will be given weekly for the first cycle, then every 2 weeks in combination with chemotherapy.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email [email protected]
Name of this trial: CODEBREAK 301
What type of cancer is this for? COLON
Phase of this trial? Phase III
Who is this trial for? Men and women with colon cancer that has spread to other parts of the body.
What biomarkers are involved? Your cancer must have a KRAS P.G12C mutation.
What is the National Clinical Trial# NCT04303780
Brief summary of trial: This trial is randomized 1:1 to either Sotorarsib+Panitumumab+FOLFIRI (standard chemo regimen) vs. standard of care chemotherapy regimens FOLFOX or FOLFIRI +/- Avastin. The study is investigating which of these treatment plans shows longer overall survival and progression-free survival in metastatic colon cancer patients.
Need to know: You may have had treatment for your colon cancer before it spread, but now that it has spread, this has to be the first treatment you receive for it.
Where is this trial available?: The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email [email protected]
Esophageal Cancer Clinical Trials
Esophageal
NAME: GEMINI GASTRIC
What type of cancer is this for? Stomach and where the stomach and esophagus join together
Phase: II
Who is this trial for: Men and women who have stomach cancer, or cancer where the stomach and esophagus meet, that cannot be removed or has spread to other parts of the body
What biomarkers are involved? Your tumor CANNOT be positive for HER-2.
What is National Clinical Trial #? NCT05702229
Brief summary of trial: This trial is looking to see how well two new drugs (MEDI5752 and AZD2936) work with chemotherapy plans that already exist.
Need to know: This must be the first treatment you receive since finding out your cancer has spread.
Where is this trial available? The Cancer & Hematology Centers
For more information, please call 616-975-3065 or email [email protected]
Name of this trial: KEYMAKER-U06, MK-3475-06C
What type of cancer is this for? Locally advanced unresectable/metastatic Gastroesophageal Adenocarcinoma (Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, and Esophageal Adenocarcinoma)
Who is this trial for? Newly diagnosed advanced gastroesophageal, gastric, esophageal cancers, that are not treatable with radiation or surgery.
What biomarkers are involved? Must be HER2 negative
What is the National Clinical Trial #? NCT06469944
Brief summary of this trial: This is a randomized trial with 2 different arms. Arm 1 is treatment with standard of care drugs, Pembrolizumab + chemotherapy. Arm 2 is the investigational arm where patient would receive investigational drug (MK-2870) + Pembrolizumab + chemotherapy. 1:1 randomization.
Need to know: Locally advanced tumor that cannot be treated with surgery or radiation and cannot have been previously treated.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 email [email protected]
Name of this trial: KEYMAKER-U06, MK-3475-06D
What type of cancer is this for? Gastroesophageal junction, Gastroesophageal adenocarcinoma, Esophageal Adenocarcinoma
Who is this trial for? Patients who have had First Line treatment for Gastric adenocarcinoma, GEJ adenocarcinoma, or esophageal carcinoma, and had disease progression during or after treatment.
What biomarkers are involved? Must be HER2 negative
What is the National Clinical Trial #? NCT06445972
Brief summary of this trial: This is a randomized trial with 2 arms. Arm 1 is standard of care Ramucirumab + paclitaxel, and Arm 2 is Investigational Drug (MK-2870) + Paclitaxel. This is a 1:1 randomization.
Need to know: Patient must have progressed during or after first line treatment for this type of cancer. First line therapy containing any Platinum drug with 5-FU, with or without immunotherapy.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 email [email protected]
Gallbladder Cancer Clinical Trials
Gallbladder
NAME: PanTumor3- Biliary Tree
What type of cancer is this for: Liver, gallbladder, bile ducts
Phase: II
Who is this trial for: Men and women who have cancer in their biliary tract: liver and/or gallbladder and/or bile ducts that has spread to other parts of the body and cannot be taken out.
What biomarkers are involved? Your cancer cells must be positive for Trop2
What is National Clinical Trial #? NCT05489211
Brief summary of trial: This trial is looking to see how well the study drug (Dato-DXd) works on biliary tract cancers that have spread, as well as how safe the drug is.
Need to know: You need to have tried either Gemzar & Carboplatin OR Gemzar & Cisplatin in the past.
Where is this trial available? The Cancer & Hematology Centers
For more information, please call 616-975-3065 or email [email protected]
Gastric Cancer Clinical Trials
Gastric
Name of this trial: Gemini-PeriOp
What type of cancer is this for? Gastroesophageal Cancer
Who is this trial for? Patients with locally advanced, resectable gastroesophageal cancer
What biomarkers are involved? Multiple cohorts include CLDN18.2, HER2 positive, and all-comers
What is the National Clinical Trial #? NCT07069712
Brief summary of this trial: Open-Label, Multi-Drug, Multi-Center, Phase II Platform Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Tumor Activity of Novel Agents or Combinations as Perioperative Treatment
Need to know: No previous treatment for unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma. Tissue from biopsy required for central determination of mutational status.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email [email protected]
Name of this trial: Artemide Gastric-01
What type of cancer is this for? Gastric Cancer
Who is this trial for? Patients who have been diagnosed with gastric cancer and have not received any prior treatments.
What biomarkers are involved? HER2+
What is the National Clinical Trial #? NCT06764875
Brief summary of this trial: Randomized, Phase 3 trial of rilvegostomig in combination with fluoropyrimidine and trastuzumab deruxtecan VS. trastuzumab, chemotherapy and pembrolizumab (standard of care arm).
Need to know: Must be HER2 positive. Tissue from previous surgery or biopsy will be sent to sponsor for confirmation of HER2 status, even if status is already known from initial testing.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email [email protected]
NAME: GEMINI GASTRIC
What type of cancer is this for? Stomach and where the stomach and esophagus join together
Phase: II
Who is this trial for: Men and women who have stomach cancer, or cancer where the stomach and esophagus meet, that cannot be removed or has spread to other parts of the body
What biomarkers are involved? Your tumor CANNOT be positive for HER-2.
What is National Clinical Trial #? NCT05702229
Brief summary of trial: This trial is looking to see how well two new drugs (MEDI5752 and AZD2936) work with chemotherapy plans that already exist.
Need to know: This must be the first treatment you receive since finding out your cancer has spread.
Where is this trial available? The Cancer & Hematology Centers
For more information, please call 616-975-3065 or email [email protected]
Name of this trial: KEYMAKER-U06, MK-3475-06C
What type of cancer is this for? Locally advanced unresectable/metastatic Gastroesophageal Adenocarcinoma (Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, and Esophageal Adenocarcinoma)
Who is this trial for? Newly diagnosed advanced gastroesophageal, gastric, esophageal cancers, that are not treatable with radiation or surgery.
What biomarkers are involved? Must be HER2 negative
What is the National Clinical Trial #? NCT06469944
Brief summary of this trial: This is a randomized trial with 2 different arms. Arm 1 is treatment with standard of care drugs, Pembrolizumab + chemotherapy. Arm 2 is the investigational arm where patient would receive investigational drug (MK-2870) + Pembrolizumab + chemotherapy. 1:1 randomization.
Need to know: Locally advanced tumor that cannot be treated with surgery or radiation and cannot have been previously treated.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 email [email protected]
Name of this trial: KEYMAKER-U06, MK-3475-06D
What type of cancer is this for? Gastroesophageal junction, Gastroesophageal adenocarcinoma, Esophageal Adenocarcinoma
Who is this trial for? Patients who have had First Line treatment for Gastric adenocarcinoma, GEJ adenocarcinoma, or esophageal carcinoma, and had disease progression during or after treatment.
What biomarkers are involved? Must be HER2 negative
What is the National Clinical Trial #? NCT06445972
Brief summary of this trial: This is a randomized trial with 2 arms. Arm 1 is standard of care Ramucirumab + paclitaxel, and Arm 2 is Investigational Drug (MK-2870) + Paclitaxel. This is a 1:1 randomization.
Need to know: Patient must have progressed during or after first line treatment for this type of cancer. First line therapy containing any Platinum drug with 5-FU, with or without immunotherapy.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 email [email protected]
Kidney Cancer Clinical Trials
Kidney
Name of this trial: Artemide-HCC01
What type of cancer is this for? Advanced Hepatocellular Cancer
Who is this trial for? Patients who have advanced kidney cancer that have not had prior treatment in advanced setting.
What biomarkers are involved? Central PD-L1 testing, however positivity not dependent on inclusivity
What is the National Clinical Trial #? NCT06921785
Brief summary of this trial: Phase 3, randomized, open-label, sponsor-blinded, study of rilvegostomig in combination with bevacizumab w/wo Tremelimumab, as 1L treatment in patients with advanced hepatocellular carcinoma.
Need to know: Randomized portion has 3 potential arms 1:1:1 randomization. Arm A: Tremelimumab/Rilvesgostomig/Bevacizumab, Arm B: Rilvesgostomig/Bevacizumab, Arm C: Bevacizumab/Atezolizumab (Standard of care arm)
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email [email protected]
Leukemia Clinical Trials
Leukemia
Name of this trial: BGB-11417-303/CLL-RR1
What type of cancer is this for? Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Who is this trial for? Relapsed and/or Refractory
What biomarkers are involved? CLL Cytogenics (eg, del(17p), del(11q), del(13q), and trisomy 12), complex karyotype, and the mutational status of relevant genes such as IGHV, TP53, and other CLL-related prognosis mutations.
What is the National Clinical Trial #? NCT06943872; https://www.clinicaltrials.gov/study/NCT06943872
Brief summary of this trial: A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Need to know: Have confirmed diagnosis of CLL/SLL and received one or more prior therapies for CLL/SLL. For reach line of therapy, patients must have received at least 2 cycles of therapy.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065
Liver Cancer Clinical Trials
Liver
NAME: PanTumor3- Biliary Tree
What type of cancer is this for: Liver, gallbladder, bile ducts
Phase: II
Who is this trial for: Men and women who have cancer in their biliary tract: liver and/or gallbladder and/or bile ducts that has spread to other parts of the body and cannot be taken out.
What biomarkers are involved? Your cancer cells must be positive for Trop2
What is National Clinical Trial #? NCT05489211
Brief summary of trial: This trial is looking to see how well the study drug (Dato-DXd) works on biliary tract cancers that have spread, as well as how safe the drug is.
Need to know: You need to have tried either Gemzar & Carboplatin OR Gemzar & Cisplatin in the past.
Where is this trial available? The Cancer & Hematology Centers
For more information, please call 616-975-3065 or email [email protected]
Lung Cancer Clinical Trials
Lung
Name of this trial: Artemide Lung-03
What type of cancer is this for? Metastatic Non-Small Cell Lung Cancer (NSCLC)
Who is this trial for? Participants who have not had treatment for their metastatic non-squamous lung cancer. Early-stage treatment in curative setting is permitted.
What biomarkers are involved? PD-L1
What is the National Clinical Trial #? NCT06627647
Brief summary of this trial: Double-blinded trial of Rilvegostomig or Pembrolizumab (Keytruda) in combination with chemotherapy for first line treatment of metastatic non-squamous, non-small cell lung cancer, whose tumor express PD-L1. Both arms of study will receive the same chemotherapy regimen, and the Rilvegostomig/Pembrolizumab will be blinded to site and patient.
Need to know: All participants in this trial will be receiving some form of treatment. There is no placebo. The trial is looking for best possible medication in this sub-disease population of lung cancer. All medications being used are either already approved for this disease type or are approved for similar disease type in either earlier or later stages of the disease.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email [email protected]
Name of this trial: Artemide Lung 02
What type of cancer is this for? Metastatic Squamous Cell Non-small Cell Lung Cancer
Who is this trial for? Squamous cell non-small cell lung cancer patients who have not received any prior treatment for metastatic disease. You may have received treatment for early-stage lung cancer.
What biomarkers are involved? PD-L1 which will be confirmed by central lab
What is the National Clinical Trial #? NCT06692738
Brief summary of this trial: This is a phase 3, randomized, double-blinded trial of Rilvegostomig or Pembrolizumab in combination with chemotherapy for patients who have not been treated for metastatic disease. All patients will receive chemotherapy and will receive 1 of 2 drugs mentioned above, however because the trial is blinded, no one will know which of the medications you are receiving, other then the sponsor.
Need to know: All participants in this trial will be receiving some form of treatment. There is no placebo. The trial is looking for best possible medication in this sub-disease population of lung cancer. All medications being used are either already approved for this disease type or are approved for similar disease type in either earlier or later stages of the disease.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email [email protected]
Name of this trial: Interpath-002
What type of cancer is this for? Resected Stage II, IIIA, IIIB, non-small cell Lung Cancer
Who is this trial for? Patients who have had their lung cancer completed resected, with no evidence of disease and have completed post-surgical chemotherapy.
What biomarkers are involved? none
What is the National Clinical Trial #? NCT06077760
Brief summary of this trial: This is a phase 3, double-blinded, randomized, placebo- and active comparator controlled trial of V940 vaccine or placebo, plus pembrolizumab after non-small lung cancer resection. This is considered adjuvant treatment (treatment given after primary treatment to reduce risk of cancer returning) where all participants will receive pembrolizumab immunotherapy with/without vaccine.
Need to know: Randomization is 1:1 for either vaccine or placebo, no one will know what patient is receiving (double-blinded).Vaccine is tailored to each individual based on their cellular makeup and is given as injection in the muscle every 3 weeks. Pembrolizumab is given IV every 6 weeks.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email [email protected]
Name of this trial: LIVIGNO-4
What type of cancer is this for? Non-Small Cell Lung Cancer, Non-Squamous Cell Cytology
Who is this trial for? Patients with Lung Cancer that has metastasized to other areas of body who have never received treatment for their disease.
What biomarkers are involved? NO EGFR, or NO ALK mutations allowed.
What is the National Clinical Trial #? NCT06236438
Brief summary of this trial: Randomized study looking at Livmoniplimab plus Budigalimab in combination with standard of care chemotherapy vs. Pembrolizumab plus standard of care chemotherapy.
Need to know: Patients must not have had any treatment for their metastatic lung cancer to be eligible for this trial. Patients may have received treatment for earlier stage of lung cancer as long as it was 6 months or greater from the time of progression of disease.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email [email protected]
Name of Trial: JUSTAR-001
What type of cancer is this trial for? Limited Stage, Small-cell Lung cancer
Who is this trial for? Patients with limited stage small cell lung cancer who have not progressed after initial chemotherapy/radiation.
What biomarkers are involved? None
National Clinical Trial # NCT06095583
Brief Summary of trial: Study is looking to compare and evaluate efficacy of new drug Tifcemalimab combined with Toripalimab vs. PLACEBO after consolidation chemotherapy for small cell lung cancer. This is a blinded study, so patients will not know whether they are receiving investigational drug or not.
Need to know information: Must not have received prior immunotherapy for small-cell lung cancer, and cannot have extensive stage/metastatic small cell lung cancer.
Where is this trial available? The Cancer and Hematology Centers and other sites nationwide, please click on link above for other potential sites.
For more information, please call 616-975-3065 or email [email protected]
Name of Trial? Sunray-01
What type of Cancer is this for? Non-small cell Lung cancer
What biomarkers are involved? KRAS G12C-mutation, PD-L1 expression
National Clinical Trials # NCT06119581
Brief Summary of trial: Locally advanced, or metastatic non-small cell lung cancer, never treated. This is first line treatment with study drug LY3537982 (pill) or placebo, in combination with immunotherapy and chemotherapy.
Need to know information: No prior treatment for lung cancer. We will do mutation testing to determine eligibility from prior biopsy/blood sample. This is a blinded trial with study drug LY3537982/placebo. All patients will receive the oral drug but the provider nor research team will know whether you are getting drug/placebo.
Where is this trial available? The Cancer and Hematology Centers and other sites nationwide, please click on link above for other potential sites.
For more information, please call 616-975-3065 or email [email protected]
Name of this trial: Tropion-Lung 10
What type of cancer is this for? Locally advanced or Metastatic Non-Squamous Non-small cell lung cancer
Who is this trial for? Patients who have lung cancer that is not treatable with curative surgery of chemoradiation. Patients must not have received prior treatment for advanced stage non-small cell lung cancer.
What biomarkers are involved? PD-L1 expression of ≥ 50% which will be determined by central lab.
What is the National Clinical Trial #? NCT06357533
Brief summary of this trial: Phase 3, Randomized, global trial of Datopotamab Deruxtecan in combination with Rilvegostomig, or Rilvegostomig monotherapy, or Pembrolizumab monotherapy. Randomization is a 2:1:2 for the 3 different arms.
Need to know: Must be non-squamous histology. Will require baseline eye exam for all arms of trial. Patients randomized to Datopotamab Deruxtecan will need further eye exams throughout trial.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email [email protected]
Lymphoma Clinical Trials
Lymphoma
Name of this trial: BGB-11417-303/CLL-RR1
What type of cancer is this for? Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Who is this trial for? Relapsed and/or Refractory
What biomarkers are involved? CLL Cytogenics (eg, del(17p), del(11q), del(13q), and trisomy 12), complex karyotype, and the mutational status of relevant genes such as IGHV, TP53, and other CLL-related prognosis mutations.
What is the National Clinical Trial #? NCT06943872; https://www.clinicaltrials.gov/study/NCT06943872
Brief summary of this trial: A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Need to know: Have confirmed diagnosis of CLL/SLL and received one or more prior therapies for CLL/SLL. For reach line of therapy, patients must have received at least 2 cycles of therapy.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065
Name of this trial: CELESTIAL-RRMCL
What type of cancer is this for? Mantle Cell Lymphoma
Who is this trial for? Patients who have relapsed or refractory Mantle cell lymphoma.
What biomarkers are involved? n/a
What is the National Clinical Trial #? NCT06742996
Brief summary of this trial: Phase 3 randomized, double-blinded trial of sonrotoclax plus zanubrutinib VS. placebo plus Zanubrutinib in patients with relapsed/refractory mantle cell lymphoma.
Need to know: Patients may have had 1-5 different lines of prior therapy. These medications are both oral medications but do require long clinic visits in the beginning of the study. No prior allogenic stem cell transplant within 6 months to starting trial and no prior autologous stem cell transplant within 3 months of starting the trial.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email [email protected]
Name of this trial: Olympia-2, R1979-ONC-2075
What type of cancer is this trial for? Untreated Follicular Lymphoma
Trial Phase: 3
Who is this trial for? This trial is for newly diagnosed or untreated patients with Follicular Lymphoma.
What biomarkers are required for eligibility? CD20+ Follicular Lymphoma
National Clinical Trial #? NCT06097364
Brief Summary of the trial: This trial is looking at how well a new drug Odronextamb combined with Chemotherapy works, and the safety of drug compared to Rituximab (already approved treatment)and Chemotherapy for follicular lymphoma.
Need to know: Must have not had any previous treatment for follicular lymphoma.
Where is this trial available? The Cancer and Hematology Centers and other various sites across the country. Please click on link above for more information.
For more information, please call 616-975-3065 or email [email protected]
Name of Trial: Olympia-3
What type of cancer is this for? Untreated patients with Diffuse Large B-Cell Lymphoma (DLBCL)
Phase of this trial? 3
Who is the trial for? Newly diagnosed patients with Diffuse large B-cell Lymphoma.
What biomarkers/mutations are necessary? CD20+
What is the National Clinical Trials info? NCT06091865
Brief summary of Trial: Patients who are eligible will receive standard of care chemotherapy (CHOP) plus investigational drug Odronextamab. Odronextamab is the investigation drug and will require frequent infusions/frequent check-in visits due to step-up dosing during the first 6 weeks. After the first 6 weeks treatment will be less frequent and may be given at any of our Cancer and Hematology centers. First 6 weeks will be done at our Grand Rapids site and will require patient to stay within 20 mins of hospital. Trial will supplement monies required for patients to be close to hospital.
Need to know: See above. Flexibility in staying at hotel near hospital in Grand Rapids is required and covered by study for 1-2 nights each week for the first 6 weeks. Newly being treated for this type of disease.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email [email protected]
Melanoma Clinical Trials
Melanoma
Name of this trial: OptimUM-10
What type of cancer is this for? Uveal Melanoma
Who is this trial for? Subjects with Primary Non-metastatic Uveal Melanoma
What biomarkers are involved? Monosomy 3
What is the National Clinical Trial #? NCT07015190; https://clinicaltrials.gov/study/NCT07015190
Brief summary of this trial: A Randomized, Phase 3, Open-label Study of Neoadjuvant Darovasertib in Subjects with Primary Non-metastatic Uveal Melanoma
Need to know: Must be at high risk of metastasis defined by at least one of the following: Monosomy 3, Class 2 GEP, Stage 3 by AJCC. Must not have had previous treatment for uveal melanoma or have evidence of metastatic uveal melanoma.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email [email protected]
Name of this trial: IDE 196-001
What type of cancer is this for? Metastatic Uveal Melanoma
Who is this trial for? Patients with confirmed metastatic disease which progresses on or after most recent treatment, or for patients with no treatment in the metastatic setting.
What biomarkers are involved? GNAQ/11
What is the National Clinical Trial #? NCT03947385
Brief summary of this trial: Patients eligible for this trial will receive investigational oral drug IDE196 plus Crizotinib (oral drug), both drugs will be taken twice daily.
Need to know: All potentially eligible patients will have tumor and blood samples sent to central laboratory for confirmation of GNAQ/11. First couple weeks on trial will include long days in clinic and eye exams will be required every 4 weeks.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email [email protected]
Multiple Myeloma Clinical Trials
Multiple Myeloma
Name of this trial: Majestic-7
What type of cancer is this for? Multiple Myeloma
Who is this trial for? This trial is for patients with newly diagnosed multiple myeloma who are either ineligible or not intended for stem cell transplant as initial therapy.
What biomarkers are involved? n/a
What is the National Clinical Trial #? NCT05552222
Brief summary of this trial: This is a phase 3 randomized trial, comparing Teclistamab in combination with Daratumumab injection and lenalidomide (oral) VS. Talquetamab in combination with Daratumumab injection and lenalidomide (oral), No placebo in this trial, all patients will receive treatment.
Need to know: Teclistamab and Talquetamab are both injection medications, not IV. Both drugs recently approved to be given in outpatient setting and no longer requiring hospitalization for monitoring. Home monitoring of vital signs and required family member presence/driving after first 3 doses to ensure patient safety. First 3-4 weeks of treatment has a busy schedule, however after first cycle visits are more spaced out.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email [email protected]
Name of this trial: EXCALIBER-Maintenance
What type of cancer is this for? Newly diagnosed Multiple Myeloma (NDMM)
Who is this trial for? 1) Patients who have received 3 to 6 cycles of an induction therapy. Post-stem cell transplant consolidation is permitted. 2) Patients within 12 months from initiation of induction who achieved at least a partial response after Autologous Stem Cell Transplantation, with or without consolidation.
What biomarkers are involved? None
What is the National Clinical Trial #? NCT05827016
Brief summary of this trial: The study is comparing Iberdomide maintenance vs. Lenalidomide maintenance therapy after Autologous Stem Cell Transplantation (ASCT) in patients with newly diagnosed multiple myeloma.
Need to know: Patients will be randomized 50:50 to either Iberdomide or Lenalidomide. Both medications are oral drugs, Iberdomide is taken 21 days out of a 28-day cycle, and Lenalidomide is taken 28 days out of a 28-day cycle. Treatment continues until progression of disease or until medications are not tolerated by patient.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email [email protected]
Myelodysplastic Syndrome Clinical Trials
Multiple Myeloma
Name of this trial: Majestic-7
What type of cancer is this for? Multiple Myeloma
Who is this trial for? This trial is for patients with newly diagnosed multiple myeloma who are either ineligible or not intended for stem cell transplant as initial therapy.
What biomarkers are involved? n/a
What is the National Clinical Trial #? NCT05552222
Brief summary of this trial: This is a phase 3 randomized trial, comparing Teclistamab in combination with Daratumumab injection and lenalidomide (oral) VS. Talquetamab in combination with Daratumumab injection and lenalidomide (oral), No placebo in this trial, all patients will receive treatment.
Need to know: Teclistamab and Talquetamab are both injection medications, not IV. Both drugs recently approved to be given in outpatient setting and no longer requiring hospitalization for monitoring. Home monitoring of vital signs and required family member presence/driving after first 3 doses to ensure patient safety. First 3-4 weeks of treatment has a busy schedule, however after first cycle visits are more spaced out.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email [email protected]
Name of this trial: EXCALIBER-Maintenance
What type of cancer is this for? Newly diagnosed Multiple Myeloma (NDMM)
Who is this trial for? 1) Patients who have received 3 to 6 cycles of an induction therapy. Post-stem cell transplant consolidation is permitted. 2) Patients within 12 months from initiation of induction who achieved at least a partial response after Autologous Stem Cell Transplantation, with or without consolidation.
What biomarkers are involved? None
What is the National Clinical Trial #? NCT05827016
Brief summary of this trial: The study is comparing Iberdomide maintenance vs. Lenalidomide maintenance therapy after Autologous Stem Cell Transplantation (ASCT) in patients with newly diagnosed multiple myeloma.
Need to know: Patients will be randomized 50:50 to either Iberdomide or Lenalidomide. Both medications are oral drugs, Iberdomide is taken 21 days out of a 28-day cycle, and Lenalidomide is taken 28 days out of a 28-day cycle. Treatment continues until progression of disease or until medications are not tolerated by patient.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email [email protected]
Myelofibrosis Clinical Trials
Myelofibrosis
Name of Trial: Karyopharm XPORT-MF-034
What type of Cancer is this for? Myelofibrosis (Blood cancer)
Phase: 3
Who is this trial for? Patients with myelofibrosis or post-essential thrombocythemia (ET) or postpolycythemia-vera (PV) myelofibrosis.
What biomarkers involved? None
What is the National Clinical Trial #? NCT04562389
Brief Summary: Purpose of this study is to evaluate the drug Selinexor in combination with Ruxolitinib vs. Placebo plus Ruxolitinib. This is a double-blinded randomized clinical trial with 2:1 ratio.
Need to know: This trial is for patients who have not yet had any treatment for their blood cancer.
Where is this trial available? This trial is available at The Cancer and Hematology at Lemmon-Holton Cancer Pavilion, and at The Cancer and Hematology Centers in Muskegon. This trial is also available at other sites nationwide.
For more information, please call 616-975-3065 or email [email protected]
Pancreatic Cancer Clinical Trials
Pancreas
Name of this trial: MountainTap-30
What type of cancer is this for? Pancreatic Cancer
Who is this trial for? Patients with treatment naïve metastatic pancreatic cancer
What biomarkers are involved? MTAP deletion
What is the National Clinical Trial #? NCT07076121 https://clinicaltrials.gov/study/NCT07076121?term=NCT07076121&rank=1
Brief summary of this trial: A Randomized, Phase 2/3 Study Comparing BMS-986504 in Combination with Nab-paclitaxel and Gemcitabine versus Placebo in Combination with Nab-paclitaxel and Gemcitabine in Participants with Untreated Metastatic Pancreatic Ductal Adenocarcinoma Harboring Homozygous MTAP Deletion
Need to know: Patients must not have received any treatment in the metastatic setting. Must have MTAP deletion which will be verified through central testing.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065
Prostate Cancer Clinical Trials
Prostate
Name of this trial: Ideate-Prostate-01
What type of cancer is this for? Prostate Cancer
Who is this trial for? Patients with metastatic castration-resistant prostate cancer
What biomarkers are involved? n/a
What is the National Clinical Trial #? NCT06925737
Brief summary of this trial: A Phase 3, Open-label Study of Ifinatamab Deruxtecan Versus Docetaxel in Participants with Metastatic Castration-Resistant Prostate Cancer (mCRPC).
Need to know: Must have had progression of disease while on androgen deprivation therapy (ADT)(or post bilateral orchiectomy) within 6 months prior to entering study. Has received prior treatment with 1 or 2 androgen receptor pathway inhibitor (ARPI) and progressed during or after at least 8 weeks of treatment.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email [email protected]
Name of this trial: MK-5684-004
What type of cancer is this for? PROSTATE cancer
Phase of this trial? Phase III
Who is this trial for? Men with prostate cancer that has spread while taking a next generation hormonal agent.
What biomarkers are involved? None
What is the National Clinical Trial# NCT06136650
Brief summary of trial: This trial is comparing the study drug (MK-5684) to two other drugs, looking to prove that the study drug helps men live longer. It is randomized 1:1.
Need to know: Your prostate cancer must be castration resistant (cancer that continues to grow even when the testosterone levels are at or below the castrate level) and your disease has to have progressed when you were on or after you received a Next Generation Hormonal Agent such as enzalutamide, abiraterone acetate, apalutamide, and darolutamide.
Where is this trial available?: The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email [email protected]
Registry Trials
Registry Trial
NAME: EXACT- Registry trial
What kind of cancer is this for? All cancer types
Phase: N/A
Who is this trial for? Men and women who either have a diagnosis of cancer, a clinical suspicion of cancer, a diagnosis of recurrent cancer or a clinical suspicion of recurrent cancer.
What biomarkers are involved? Multiple
What is National Clinical Trial #?
Brief summary of trial: This study is looking at tissue and blood samples from cancer patients, to study the biomarkers they find in the blood or tissue to help and come up with future therapies.
Need to know: There are no medications in this trial, you would need to give a blood or tissue sample for the sponsor to evaluate.
Where is this trial available? The Cancer & Hematology Centers
For more information, please call 616-975-3065 or email [email protected]
NAME: Oracle- Registry trial
What kind of cancer is this for? All types
Phase: N/A
Who is this trial for? The primary study population will include participants with invasive bladder, ureteral, or renal pelvis carcinoma, non-small cell lung cancer, and breast cancer. Exploratory cohorts include participants with cutaneous melanoma, esophageal carcinoma, gastroesophageal junction carcinoma, gastric adenocarcinoma, pancreatic adenocarcinoma, squamous cell carcinoma of the head and neck, epithelial ovarian/Fallopian tube carcinoma, endometrial cancer, renal cell carcinoma (RCC), and rectal adenocarcinoma.
What biomarkers are involved? None
What is National Clinical Trial #? NCT05059444
Brief summary of trial: This study wants to test an assay that they have developed, which could help detect recurrence in people with certain tumors.
Need to know: There are no medications on this trial, just blood draws and tissue samples are needed.
Where is this trial available? The Cancer & Hematology Centers
For more information, please call 616-975-3065 or email [email protected]
Urothelial Cancer Clinical Trials
Urothelial
Name of this trial: TROPION-Urothelial03
What type of cancer is this for? Urothelial Carcinoma
Who is this trial for? Subjects With Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC)
What biomarkers are involved? TROP2 Protein Expression
What is the National Clinical Trial #? NCT07129993; https://clinicaltrials.gov/study/NCT07129993
Brief summary of this trial: A Randomized, Open-Label, Phase 2/3 Study of Datopotamab Deruxtecan (Dato-DXd) plus Carboplatin or Cisplatin versus Gemcitabine plus Carboplatin or Cisplatin in Participants with Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC) who Progressed During or After Enfortumab Vedotin (EV) plus Pembrolizumab Combination Treatment
Need to know: Must have confirmed unresectable locally advanced (T4b, any N; or any T, N 2-3) or metastatic (any T, any N, M1) urothelial carcinoma of the bladder, renal pelvis, ureter, or urethra. No prior systemic treatment other than the combination of EV and pembrolizumab.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email [email protected]
Name of this trial: RC48 G001 (SEAGEN)
What type of cancer is this for? Locally advanced or metastatic Urothelial Carcinoma
Who is this trial for? Patients locally advanced, unresectable, or metastatic urothelial carcinoma, including urothelial originating from the renal pelvis, ureters, bladder, or urethra.
What biomarkers are involved? HER2 positive which will be centrally confirmed.
What is the National Clinical Trial #? NCT04879329
Brief summary of this trial: Trial is evaluating safety and efficacy of Disitamab Vedotin alone or in combination with Pembrolizumab. Patients who have had 1 or 2 previous lines of treatment will receive study drug every 2 weeks. Patients who have not been treated for locally advanced or metastatic disease will receive either study drug every 2 weeks with Pembrolizumab every 6 weeks, or study drug only every 2 weeks.
Need to know: Patients can have received 0, 1, or 2 lines of previous systemic therapy for locally or metastatic disease and progressed. Patients must have received an anti-PD-1 therapy.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email [email protected]